PDCD1 and non-small cell lung carcinoma: To further investigate the predictive capacity of NSD3 for the clinical outcome of immunotherapy, we mined bulk RNA-Seq data and clinical information from one NSCLC immunotherapy cohort treated with anti-PD-1/PD-L1.